142935-60-2

Basic information

• Product Name: 2-(Benzofuran-5-yl)acetic Acid
• Synonyms: 2-(Benzofuran-5-yl)acetic Acid;Benzofuran-5-yl-Acetic Acid;5-Benzofuranacetic acid
• CAS NO: 142935-60-2
• Molecular Formula: C₁₀H₈O₃
• Molecular Weight: 176.16872
• Mol File: 142935-60-2.mol

Chemical Properties

• Boiling Point: 331.1±17.0 °C(Predicted)
• Appearance: /
• Density: 1.316±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.22±0.30(Predicted)
• CAS DataBase Reference: 2-(Benzofuran-5-yl)acetic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Benzofuran-5-yl)acetic Acid(142935-60-2)
• EPA Substance Registry System: 2-(Benzofuran-5-yl)acetic Acid(142935-60-2)

Safety Data

• Hazardous Substances Data: 142935-60-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(Benzofuran-5-yl)acetic Acid is used as a reactant for the preparation of α2-antagonist/5-HT uptake inhibitors. These inhibitors serve as antidepressant agents, helping to alleviate symptoms of depression by modulating the levels of certain neurotransmitters in the brain. The compound's unique structure allows it to interact with specific receptors and transporters, making it a valuable component in the development of novel antidepressant medications.

Upstream product

• 69999-16-2 2,3-dihydrobenzofuran-5-acetic acid 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 156-38-7 4-hydroxyphenylacetate 
• 1158745-04-0 5-ethynylbenzo[b]furane 
• 142935-51-1 ethyl 2-(benzofuran-5-yl)acetate 
• 142935-50-0 ethyl 2-(4-(2,2-diethoxyethoxy)phenyl)acetate 
• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 
• 121638-36-6 methyl 2-(benzofuran-5-yl)acetate 

Downstream Products

• 69999-16-2 2,3-dihydrobenzofuran-5-acetic acid 
• 87776-76-9 5-(2-hydroxyethyl)-2,3-dihydrobenzofuran 
• 127264-14-6 2,3-dihydro-5-(2-bromoethyl)benzofuran 
• 121638-36-6 methyl 2-(benzofuran-5-yl)acetate 

Relevant articles and documents

ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

Oxidation of Alkynyl Boronates to Carboxylic Acids, Esters, and Amides

A general efficient protocol was developed for the synthesis of carboxylic acids, esters, and amides through oxidation of alkynyl boronates, generated directly from terminal alkynes. This protocol represents the first example of C(sp)?B bond oxidation. This approach displays a broad substrate scope, including aryl and alkyl alkynes, and exhibits excellent functional group tolerance. Water, primary and secondary alcohols, and amines are suitable nucleophiles for this transformation. Notably, amino acids and peptides can be used as nucleophiles, providing an efficient method for the synthesis and modification of peptides. The practicability of this methodology was further highlighted by the preparation of pharmaceutical molecules.

Preparation method of acid with different substituent groups

The invention discloses a preparation method of an acid with different substituent groups. A terminal alkyne is lithiated with n-butyllithium, and then reacts with isopropoxyboronic acid pinacol ester, hydrogen chloride is added to achieve quenching, then the obtained reaction product is oxidized by an oxidizing agent, and the oxidized reaction product is separated and purified to obtain the acid.The method of the invention has the advantages of simplicity in operation, one-pot process preparation, no metal catalysis, nontoxic reagents, greenness, environmental friendliness and high atomic utilization rate, and provides a novel and quick way for preparing the acid with different substituent groups; and the obtained acid is an important fine chemical product, and can be widely used in fields of medicines, pesticides, spices and other industries.

Darifenacin intermediate 2, 3 - dihydro - 5 - benzofuran acetic acid preparation new method of (by machine translation)

The invention relates to a darifenacin intermediate - 2, 3 - dihydro - 5 - benzofuran acetic acid. By the P-hydroxy-acetic acid and bromo acetaldehyde acetal as the starting material, the presence of O - alkylation reaction under a condition of the corresponding ether compound; then by esterification reaction to obtain the corresponding ester; in PPA (poly phosphoric acid) under the action of the, cyclization to obtain 2, 3 - benzofuran - 5 - acetate; 2, 3 - benzofuran - 5 - acetic acid layer which hydrolysis, to acidify the corresponding carboxylic acid; obtained by catalytic hydrogenation of 2, 3 - dihydro - 5 - benzofuran acetic acid; or the first 2, 3 - benzofuran - 5 - acetate obtained by catalytic hydrogenation of 2, 3 - dihydro - 5 - benzofuran acetic acid esters; and hydrolyzed, acidified to obtain 2, 3 - dihydro - 5 - benzofuran acetic acid. The method of the invention by simple and safe, each reaction raw materials are cheap and easy to obtain, the reaction yield is high, and is particularly suitable for industrial production of 2, 3 - dihydro - 5 - benzofuran acetic acid. (by machine translation)

ACYLHYDRAZONES AS KINASE MODULATORS

Abstract The invention is directed to acylhydrazones compounds of Formula I: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same

The present invention relates to compounds of formula (I): 1in which R1 represents a hydrogen or halogen atom, or a group CF3; R2 and R3 represent, independently, a hydrogen atom or a methyl group; n and n′ each

Structure-activity studies for a novel series of N-(arylethyl)-N- (1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines possessing dual 5- HT uptake inhibiting and α2-antagonistic activities

In search of an α2-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the α2-receptor (K(i) = 6.71 nM) and

Monospecific antibodies useful in evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones

Inhibitors of human leukocytes elastase are known to be useful in the treatment of a wide variety of antiinflammatory and antidegenerative diseases. In inhibiting elastase, the therapeutic agents are shown to form a characteristic stable complex with the enzyme. In the radioimmunoassay disclosed herein, the inhibitor-enzyme complex is advantageously hydrolyzed and specific product(s) of the hydrolysis are measured utilizing polyclonal antibodies capable of binding to one or more haptens of formula II STR1 wherein M is allyl or n-propyl, Z1 is (a) 5-benzofuranyl or (b) substituted phenyl wherein the substituent is methyl or ethyloxy. The assays utilizing these antibodies are useful in a clinical setting, for determining appropriate dosage and assessing the effectiveness of treatment.